ASH 2019 | First-in-human trial of a BCMA-CD19 compound CAR in B-ALL
Fang Liu, MD, PhD, Chengdu Military General Hospital, Chengdu, China, discusses the first-in-human phase I trial of the BCMA-CD19 compound CAR (cCAR) with remarkable donor-specific antibody reduction. This agent is a 2-unit CAR composed of a complete BCMA-CAR fused to a complete CD19-CAR by a self-cleaving P2A peptide, enabling independent expression of both CAR receptors separately on the T-cell surface. Results appear promising, and suggest the agent has potential to be applied beyond the realm of hematological diseases and can benefit patients receiving solid organ transplants or those with other antibody-mediated diseases. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
